<DOC>
	<DOCNO>NCT00925600</DOCNO>
	<brief_summary>This phase 3 , randomize , double-blind , placebo-controlled study evaluate new worsen lens opacification subject non-metastatic prostate cancer receive denosumab bone loss due androgen deprivation therapy .</brief_summary>
	<brief_title>A Study Evaluate New Worsening Lens Opacifications Subjects With Non-metastatic Prostate Cancer Receiving Denosumab Bone Loss Due Androgen-Deprivation Therapy</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Cataract</mesh_term>
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Bone Diseases , Metabolic</mesh_term>
	<mesh_term>Denosumab</mesh_term>
	<mesh_term>Androgens</mesh_term>
	<criteria>Men â‰¥ 30 year age nonmetastatic prostate cancer , undergone bilateral orchiectomy initiate ADT GnRH agonists expect continue ADT least 12 month Adequate visual accuracy allow eye test Bone Mineral Density ( BMD ) requirement : Osteopenia 70 year age ; Osteopenia normal BMD 70 year age Signed informed consent Previous surgery cataract eye , current diagnosis cataract , cataract surgery foreseen near future , ocular disease lead visual loss Diagnosis osteoporosis</criteria>
	<gender>Male</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>120 Years</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Lens Opacification</keyword>
	<keyword>Bone Loss</keyword>
	<keyword>Androgen Deprivation Therapy</keyword>
	<keyword>Non-metastatic prostate cancer</keyword>
</DOC>